Propeller health enters Japan via collaboration with Novartis to connect the Propeller digital health platform to Enerzair and Atectura Breezhaler
26 Aug 2020
Patients in Japan using Enerzair and Atectura Breezhaler to manage uncontrolled Asthma will have the option to enroll in Propeller’s digital health platform to help manage their condition
Propeller’s platform works by attaching a sensor to the inhaler which then delivers objective data on medication use to the Propeller app on the patient’s smartphone
The app will send patient reminders and keep a record of adherence data over time
Enerzair Breezhaler was approved in Japan on June 29, 2020 for the treatment of bronchial Asthma; Atectura Breezhaler was also approved as a LABA/ICS combination Asthma treatment
This is the second collaboration between Propeller health and Novartis ex-US where both companies first collaborated in Europe in July 2020
Propeller health enters Japan with digital health sensor for Enerzair and Atectura Breezhaler
Share this
CI Scientists Remarks:
About Propeller’s digital –
Propeller’s digital health platform includes a sensor and app. A transparent capsule lets users see the medication; the inhaler also includes an attached CE marked sensor that connects with Propeller’s smartphone app
Propeller’s app also delivers medication reminders to the user and tracks adherence data, which can then be shared with clinicians